Atherogenic lipid phenotype and lipoprotein (a) in diabetes

Endocrinologist

Volumn 12, Issue 3, 2002, Pages 243-259

  Nguyen, Chi ^a   Charles, M Arthur ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROGENIC LIPID PHENOTYPE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIRCULATION; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIAGNOSTIC VALUE; DRUG EFFICACY; GEL ELECTROPHORESIS; GENETIC LINKAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; LIVER METABOLISM; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PHENOTYPE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION;

EID: 0036274025     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-200205000-00011     Document Type: Review

References (126)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
2. Diabetes, other risk factors, and 12 year-cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
3. Arrhythmias and mortality after myocardial infarction in diabetic patients
4. Impact of diabetes on mortality after the first myocardial infarction
5. The Scandinavian Simvastatin Survival Study (4S) Group: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with CHD
6. For the CARE Investigators: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial
7. Low-density lipoprotein subclass patterns and risk of myocardial infarction
8. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes
9. Small, dense LDL particles as a predictor of the risk of ischemic heart disease in men
10. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
11. Role of plasma triglyceride in the regulation of plasma (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart risk
12. Prospective study of small LDLs as a risk factor for NIDDM in elderly men and women
13. High-density lipoproteins and coronary atherosclerosis
14. Relation of angiographically defined coronary disease to plasma lipoprotein subfractions and apolipoproteins
15. Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis
16. The new pathophysiology of coronary artery disease
17. American Diabetes Association, position statement: Management of dyslipidemia in adults with diabetes
18. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults
19. Prevalence of lipid abnormalities, awareness, and treatment in U.S. adults with diabetes
20. Diabetic (DM) dyslipidemia and the high prevalence of the atherogenic lipid profile (ALP) and Lp(a)
21. Beyond LDL cholesterol reductions
22. Antiatherothrombotic properties of statins
23. Anti-inflammatory action of statins and reduction of homocystinemia by vitamin supplementation: Interactions among strategies for cardiovascular prevention
24. Pleiotropic effects of statins and their clinical significance
25. LDL-Cholesterol is significantly lower in diabetic than in non-diabetic coronary patients
26. The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
27. Lipoprotein Lp(a) excess and CHD
28. Effect of gender, age, and lipids status on low-density lipoprotein subfraction distribution: Results from the Framingham Offspring Study
29. Differences in low-density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women
30. Optimization of glycemic control by insulin therapy decreases the proportion of small, dense LDL particles in diabetic patients
31. Coronary artery disease in IDDM: Gender differences in risk factors but not risk
32. Greater effects of diabetes on LDL size in women than in men
33. Sex difference in ischemic heart disease mortality in diabetics: A prospective population-based study
34. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctions
35. Risk factors for coronary heart disease in diabetes mellitus
36. Differences in lipoprotein subfraction composition and distribution between type 1 diabetic men and control subjects
37. Effects of a short-acting insulin analog (insulin lispro) versus regular insulin on lipid metabolism in insulin-dependent diabetes mellitus
38. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPD:23)
39. HDLs containing apolipoprotein A-I and A-II (LpA-I: A-II) as markers of coronary artery disease in men with NIDDM
40. Whole-plasma and high-density lipoprotein subfraction surface lipid composition in IDDM men
41. High lipoprotein(a) levels in type 1 and type 2 diabetic patients with microalbuminuria
42. Levels of Lp(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM: Results from follow-up in the diabetes control and complications trial
43. Low-density lipoprotein particle size and coronary artery disease
44. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women
45. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians
46. Evidence for a new pathophysiological mechanism for coronary artery disease regression: Hepatic lipase-mediated changes in LDL density
47. New aspects of cardiovascular risk factors including small, dense LDL, homocystinemia, and Lp(a)
48. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas's Atherosclerosis Regression Study (STARS)
49. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford coronary risk intervention project
50. Low-density lipoprotein size, pravastatin treatment, and coronary events
51. Lipoprotein heterogeneity and apolipoprotein B metabolism
52. Dyslipidemia of central obesity and insulin resistance
53. Effects of insulin and asipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects
54. Fasting and postprandial determinants for the occurrence of small dense LDL species in noninsulin-dependent diabetic patients with and without hypertriglycerideaemia: The involvement of insulin, insulin precursor species and insulin resistance
55. Role of oxidized low-density lipoprotein in atherogenesis
56. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm
57. Diabetic dyslipidemia: Basic mechanisms underlying the common hypertriglyceridemia and low HDLc levels
58. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: A current review
59. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids
60. A genome search identifies major quantitative trait loci on human chromosome 3 and 4 that influence cholesterol concentrations in small LDL particles
61. Lipoprotein metabolism in hepatic lipase deficiency: Studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high-density lipoprotein
62. Inheritance of high-density lipoprotein lipase and hepatic lipase activity
63. Hepatic lipase: New insights from genetic and metabolic studies
64. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol
65. Associations of hepatic and lipoprotein lipase activities with changes in dietary composition and low-density lipoprotein subclasses
66. Reduced LDL particle size in children consuming a very-low-fat diet is related to parental LDL-subclass patterns
67. Genetic underpinnings of LDL size and density: A role for hepatic lipase?
68. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol
69. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of preparatory ultracentrifugation
70. Single-spin density-gradient ultracentrifugation vs. gradient gel electrophoresis: Two methods for detecting low-density-lipoprotein heterogeneity compared
71. Detection and quantitation of LDL subfractions
72. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy
73. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease
74. Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men
75. Lipid and lipoprotein responses to oral combined hormone replacement therapy in normolipemic obese women with controlled type 2 diabetes mellitus
76. Effects of Thiazolidinediones on lipoprotein subclasses in patients who are insulin resistant
77. Treatment of the small, dense LDL component of the atherogenic lipid profile (ALP) in diabetic patients (DP) using Niaspan (NS), Atorvastatin (A) or both (NS + A)
78. Distribution and correlates of high-density lipoprotein subclasses among children and adolescents
79. Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles
80. Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes
81. Disc electrophoresis of rat plasma lipoproteins
82. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women
83. Effect of Atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects
84. Extended release niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes
85. The global management plan
86. Can lifestyle changes reverse coronary heart disease?
87. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS)
88. Cardiovascular Risk in Diabetes: A story of missed opportunities?
89. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment
90. Low-density-lipoprotein subclasses and response to a low-fat diet in healthy men
91. Effect of gemfibrozil treatment in hypercholesterotemia on low-density lipoprotein (LDL) subclass distribution and LDL-cell interaction
92. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia
93. Regulation of lipid and lipoprotein metabolism by PPAR activators
94. Troglitazone and small low-density lipoprotein in type 2 diabetes
95. The effect of thiazolidinediones on HDL subfractions
96. Differing effects of thiazolidinediones on HDL subfractions and Lp(a)
97. Relationships between apolipoprotein(a) phenotype and increase of lipoprotein(a) by troglitazone
98. Pioglitazone reduces dense LDL-particles in patients with type-2 diabetes
99. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes
100. The atherogenic lipid profile (ALP) and sulfonylurea (SU), Metformin (MET) and insulin (INS) use in diabetes
101. Estrogen replacement decreases the level of antibodies against oxidized low-density lipoprotein in postmenopausal women with coronary heart disease
102. Effects of oral combined hormone replacement therapy on plasma lipids and lipoproteins
103. Can postmenopausal hormone replacement improve plasma lipids in women with diabetes?
104. Reduction in plasma LDL and Apo B levels with combined estrogen plus progestin therapy in post-menopausal women is greater in women with dense rather than buoyant LDL
105. The successful treatment of the atherogenic lipid profile (ALP; Small, Dense LDL, HDL2, HDLc and Triglycerides) and Lp(a) in diabetic patients (DP) using niacin
106. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT Study: A randomized trial
107. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia
108. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia
109. Equivalent efficacy of a time-release form of niacin (Niaspan) given once a night versus plain niacin in the management of hyperlipidemia
110. Niacin (N) vs. Niaspan (NS) treatment of the atherogenic lipid profile (ALP; small, dense LDL, HDL2, HDLc and triglycerides) and Lp(a) in diabetic patients
111. The Diabetes Multicenter Research Group: A double-blind, placebo-controlled, multicenter study of once-daily extended release niacin (Niaspan) in patients with type 2 diabetes: Influence of baseline characteristics on lipoproteins and glycemic control
112. Effect of fluvastatin on low-density lipoprotein peak particle diameter
113. The role of small, dense low-density lipoprotein (LDL): A new look
114. The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group: The effect of aggressive verus standard lipid lowering by atorvastatin on diabetic dyslipidemia
115. Atorvastatin (A), although minimally increasing LDL size does reduce small, dense LDL particle mass similar to Niacin (N) and Niaspan (NS) in diabetic patients
116. High dose atorvastatin therapy in women with diabetic dyslipidemia
117. Effect of atorvastatin on low-density lipoprotein subfraction profile
118. The benefits of niacin in atherosclerosis
119. Atorvastatin therapy ameliorates diabetic dyslipidemia by increasing lipoprotein lipase activity
120. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid
121. The coronary drug project research group. Clofibrate and niacin in coronary heart disease
122. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
123. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes